Duloxetine 60 to 120 mg once daily compared with placebo in the prevention of relapse in generalized anxiety disorder
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2014
At a glance
- Drugs Duloxetine (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 30 Aug 2007 Status changed from in progress to completed.
- 13 Nov 2005 New trial record.